194 related articles for article (PubMed ID: 19774657)
1. Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody.
Urva SR; Yang VC; Balthasar JP
J Pharm Sci; 2010 Mar; 99(3):1582-600. PubMed ID: 19774657
[TBL] [Abstract][Full Text] [Related]
2. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
[TBL] [Abstract][Full Text] [Related]
3. Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenografts.
Urva SR; Balthasar JP
MAbs; 2010; 2(1):67-72. PubMed ID: 20081377
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody.
Cai W; Olafsen T; Zhang X; Cao Q; Gambhir SS; Williams LE; Wu AM; Chen X
J Nucl Med; 2007 Feb; 48(2):304-10. PubMed ID: 17268029
[TBL] [Abstract][Full Text] [Related]
5. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Modeling of the Pharmacokinetics of "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibodies in Colorectal Cancer Xenograft Mouse Models.
Polli JR; Engler FA; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):674-691. PubMed ID: 30321546
[TBL] [Abstract][Full Text] [Related]
7. An ELISA for quantification of T84.66, a monoclonal anti-CEA antibody, in mouse plasma.
Urva SR; Yang VC; Balthasar JP
J Immunoassay Immunochem; 2010; 31(1):1-9. PubMed ID: 20391013
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.
Abuqayyas L; Balthasar JP
AAPS J; 2012 Sep; 14(3):445-55. PubMed ID: 22528507
[TBL] [Abstract][Full Text] [Related]
9. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice.
Beatty BG; O'Conner-Tressel M; Do T; Paxton RJ; Beatty JD
Cancer Res; 1990 Feb; 50(3 Suppl):846s-851s. PubMed ID: 2297732
[TBL] [Abstract][Full Text] [Related]
12. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn).
Ferl GZ; Wu AM; DiStefano JJ
Ann Biomed Eng; 2005 Nov; 33(11):1640-52. PubMed ID: 16341929
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
[TBL] [Abstract][Full Text] [Related]
14. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
Abuqayyas L; Balthasar JP
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
[TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen and alpha-fetoprotein expression and monoclonal antibody targeting in a human hepatoma/nude mouse model.
Wang ZF; Stein R; Sharkey RM; Goldenberg DM
Cancer Res; 1990 Feb; 50(3 Suppl):869s-872s. PubMed ID: 1688735
[TBL] [Abstract][Full Text] [Related]
16. Impact of Different Selectivity between Soluble and Membrane-bound Forms of Carcinoembryonic Antigen (CEA) on the Target-mediated Disposition of Anti-CEA Monoclonal Antibodies.
Iwano J; Shinmi D; Masuda K; Murakami T; Enokizono J
Drug Metab Dispos; 2019 Nov; 47(11):1240-1246. PubMed ID: 31533926
[TBL] [Abstract][Full Text] [Related]
17. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
19. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
Kenanova V; Olafsen T; Crow DM; Sundaresan G; Subbarayan M; Carter NH; Ikle DN; Yazaki PJ; Chatziioannou AF; Gambhir SS; Williams LE; Shively JE; Colcher D; Raubitschek AA; Wu AM
Cancer Res; 2005 Jan; 65(2):622-31. PubMed ID: 15695407
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal Cancer.
Thomas VA; Balthasar JP
AAPS J; 2016 Jul; 18(4):923-32. PubMed ID: 27029796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]